brexucabtagene autoleucel
Selected indexed studies
- Brexucabtagene Autoleucel. (, 2006) [PMID:40460224]
- Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. (Drugs Today (Barc), 2022) [PMID:35670706]
- Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. (J Clin Oncol, 2025) [PMID:39418622]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. (2023) pubmed
- Brexucabtagene Autoleucel. (2006) pubmed
- Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma. (2022) pubmed
- Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. (2022) pubmed
- Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. (2025) pubmed
- Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia. (2023) pubmed
- PMID:37797134 (2023) pubmed
- PMID:40737466 (2021) pubmed
- Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. (2024) pubmed
- Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. (2021) pubmed